AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at HCW Conference.
ByAinvest
Thursday, Aug 28, 2025 8:36 am ET1min read
Atossa Therapeutics CEO Dr. Steven Quay will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 3:00 p.m. ET. Dr. Quay will discuss Atossa's lead program, Z)-endoxifen, a highly potent Selective Estrogen Receptor Modulator (SERM) with dual mechanisms, and provide an update on the company's clinical progress and upcoming milestones.
Atossa Therapeutics (NASDAQ: ATOS), a clinical-stage biopharmaceutical company focused on breast cancer treatment and prevention, has announced that CEO Dr. Steven Quay will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 3:00 p.m. ET. During the presentation, Dr. Quay will provide an update on the company's lead program, (Z)-endoxifen, a highly potent Selective Estrogen Receptor Modulator (SERM) with dual mechanisms.(Z)-endoxifen is designed for breast cancer prevention and treatment and is currently in Phase II development for estrogen receptor-positive (ER+) breast cancer. The drug demonstrates potential across multiple stages of breast cancer management, including reducing breast tissue density to lower cancer risk, inhibiting tumor cell activity prior to surgery, and preventing recurrence or new tumor development following initial treatment.
The fireside chat will cover multiple clinical studies' progress and recent encouraging regulatory feedback that could accelerate the development of (Z)-endoxifen. The presentation will be available via webcast with a 90-day replay period on Atossa's investor website. A preview video message from Dr. Quay is currently available.
Atossa Therapeutics' focus on advancing (Z)-endoxifen for metastatic breast cancer highlights its commitment to addressing unmet medical needs in oncology. The company's recent patent grant for enteric oral formulations of (Z)-endoxifen underscores its innovative approach to breast cancer treatment.
The Selective Estrogen Receptor Modulators (SERMs) market is anticipated to witness significant expansion in the coming years, fueled by the increasing prevalence of cancer, heightened awareness of SERM therapies, and a growing pipeline of candidates in clinical trials and regulatory review [2]. Key players in the SERM market include Atossa Therapeutics, Duchesnay, Pfizer, Eli Lilly, and Sermonix Pharmaceuticals.
References:
[1] https://www.stocktitan.net/news/ATOS/atossa-therapeutics-ceo-to-discuss-clinical-progress-and-upcoming-ns3pl09vj43u.html
[2] https://www.barchart.com/story/news/34378449/serm-market-outlook-2034-clinical-trials-fda-approvals-market-size-therapies-companies-by-delveinsight
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet